Gelatine methacrylamide-based hydrogels: An alternative three-dimensional cancer cell culture system

Acta Biomaterialia

Volumn 10, Issue 6, 2014, Pages 2551-2562

  Kaemmerer, Elke ^a,b   Melchels, Ferry P W ^a,c   Holzapfel, Boris M ^a,d   Meckel, Tobias ^b   Hutmacher, Dietmar W ^a   Loessner, Daniela ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Animal model; Cell encapsulation; ECM; Hydrogel; Mechanical properties

Indexed keywords

ANIMALS; BIOMECHANICS; CELL CULTURE; CELLS; DISEASES; ENZYME ACTIVITY; HYALURONIC ACID; STIFFNESS; TUMORS;

ANIMAL MODEL; CANCER CELLS; CELL ENCAPSULATIONS; EXTRACELLULAR MATRICES; IN-VITRO; METHACRYLAMIDES; OVARIAN CANCERS; PACLITAXEL; PROLIFERATION RATE; VITRO AND IN VIVO;

HYDROGELS;

DEXTRAN; FLUORESCEIN ISOTHIOCYANATE; GELATIN; GELATINE METHACRYLAMIDE; HYALURONIC ACID; LAMININ; MATRIX METALLOPROTEINASE; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; PACLITAXEL; POLYMER; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; HYDROGEL; METHACRYLAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MULTICELLULAR SPHEROID; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; CELL CULTURE; CELL DIVISION; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; TUMOR CELL LINE;

ANIMALIA;

ACRYLAMIDES; CELL DIVISION; CELL LINE, TUMOR; CELLS, CULTURED; EXTRACELLULAR MATRIX; GELATIN; HUMANS; HYDROGELS; MATRIX METALLOPROTEINASES;

EID: 84899623868     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2014.02.035     Document Type: Article

References (71)

1. Gieni RS, Hendzel MJ. Mechanotransduction from the ECM to the genome: are the pieces now in place? J Cell Biochem 2008;104:1964-87.
2. Hubbell JA. Matrix effects. In: Lanza R, Langer R, Vacanti JP, editors. Principles of tissue engineering. New York: Academic Press; 2007.
3. Even-Ram S, Yamada KM. Cell migration in 3-D matrix. Curr Opin Cell Biol 2005;17:524-32.
4. Janmey PA, Miller RT. Mechanisms of mechanical signaling in development and disease. J Cell Sci 2011;124:9-18.
5. Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer 2011;11:512-22.
6. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000;6:324-9.
7. Hutmacher DW. Biomaterials offer cancer research the third dimension. Nat Mater 2010;9:90-3.
8. Hutmacher DW, Loessner D, Rizzi SC, Kaplan DL, Mooney DJ, Clements JA. Can tissue engineering concepts advance tumor biology research? Trends Biotechnol 2010;28:125-33.
9. Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol 2005;15:378-86.
10. Szot CS, Buchanan CF, Freeman JW, Rylander MN. 3D in vitro bioengineered tumors based on collagen I hydrogels. Biomaterials 2011;32:7905-12.
11. Liu J, Tan Y, Zhang H, Zhang Y, Xu P, Chen J, et al. Soft fibrin gels promote selection and growth of tumourigenic cells. Nat Mater 2012;11:734-41.
12. Harunaga JS, Yamada KM. Cell-matrix adhesions in 3D. Matrix Biol 2011;30:363-8.
13. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007;4:359-65.
14. Weigelt B, Bissell MJ. Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol 2008;18:311-21.
15. Pampaloni F, Reynaud EG, Stelzer EHK. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007;8:839-45.
16. DeVolder R, Kong H-J. Hydrogels for in vivo-like three-dimensional cellular studies. WIREs Syst Biol Med 2012;4:351-65.
17. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 2006;7:211-24.
18. Zhang S. Fabrication of novel biomaterials through molecular self-assembly. Nat Biotechnol 2003;21:1171-8.
19. Yang Z, Zhao X. A 3D model of ovarian cancer cell lines on peptide nanofiber scaffold to explore the cell-scaffold interaction and chemotherapeutic resistance of anticancer drugs. Int J Nanomed 2011;6:303-10.
20. Loessner D, Rizzi SC, Stok KS, Fuehrmann T, Hollier B, Magdolen V, et al. Bioengineered 3D ovarian cancer model for the assessment of peptidasemediated enhancement of spheroid growth and intraperitoneal spread. Biomaterials 2013;34:7389-400.
21. Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010;31:8494-506.
22. Van Den Bulcke AI, Bogdanov B, De Rooze N, Schacht EH, Cornelissen M, Berghmans H. Structural and rheological properties of methacrylamide modified gelatine hydrogels. Biomacromolecules 2000;1:31-8.
23. Galis ZS, Jaikirshan JK. Matrix metalloproteinases in vascular remodelling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-62.
24. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase-b or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002;37:375-536.
25. Schuurman W, Levett PA, Pot MW, Van Weeren PR, Dhert WJA, Hutmacher DW, et al. Gelatine-methacrylamide hydrogels as potential biomaterials for fabrication of tissue-engineered cartilage constructs. Macromol Biosci 2013;13:1-11.
26. Nichol JW, Koshy ST, Bae H, Hwang CM, Yamanlar S, Khademhosseini A. Cellladen microengineered gelatine methacrylate hydrogels. Biomaterials 2010;31:5536-44.
27. Nicodemus GD, Bryant SJ. Cell encapsulation in biodegradable hydrogels for tissue engineering applications. Tissue Eng Part B Rev 2008;14:149-65.
28. Williams CG, Malik AN, Kim TK, Manson PN, Elisseeff JH. Variable cytocompatibility of six cell lines with photoinitiators used for polymerizing hydrogels and cell encapsulation. Biomaterials 2005;26:1211-8.
29. Lieleg O, Baumgärtel RM, Bausch AR. Selective Filtering of Particles by the extracellular matrix: an electrostatic bandpass. Biophys J 2009;97:1569-77.
30. Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J 2008;22:276-84.
31. Lieleg O, Ribbeck K. Biological hydrogels as selective diffusion barriers. Trends Cell Biol 2011;21:543-51.
32. Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med 2005;11:678-82.
33. Fischbach C, Kong HJ, Hsiong SX, Evangelista MB, Yuen W, Mooney DJ. Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement. PNAS 2009;106:399-404.
34. Langdon SP, Smyth JF. Growth factors and ovarian cancer. Endocr Relat Cancer 1998;5:283-91.
35. Bennett NT, Schultz GS. Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg 1993;165:728-37.
36. David L, Dulong V, Le Cerf D, Chauzy C, Norris V, Delpech B, et al. Reticulated hyaluronan hydrogels: a model for examining cancer cell invasion in 3D. Matrix Biol 2004;23:183-93.
37. Anttila MA, Tammi RH, Tammi MI, Syrjänen KJ, Saarikoski SV, Kosma V. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 2000;60:150-5.
38. Gardner MJ, Catterall JB, Jones LM, Turner GA. Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis. Clin Exp Metastasis 1996;14:325-34.
39. Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, Khar RK. Role of CD44 in tumour progression and strategies for targeting. J Drug Target 2012;20:561-73.
40. Geberhiwot T, Assefa D, Kortesmaa J, Ingerpuu S, Pedraza C, Wondimu Z, et al. Laminin-8 (a4b1c1) is synthesized by lymphoid cells, promotes lymphocyte migration and costimulates T cell proliferation. J Cell Sci 2001;114:423-33.
41. Ljubimova JY, Lakhter AJ, Loksh A, Yong WH, Riedinger MS, Miner JH, et al. Overexpression of a4 chain-containing laminins in human glial tumors identified by gene microarray analysis overexpression of a4 chaincontaining laminins in human glial tumors identified by gene microarray analysis. Cancer Res 2001;61:5601-10.
42. Ahmed N, Riley C, Rice G, Quinn M. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis 2005;22:391-402.
43. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 2009; 113:143-8.
44. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16.
45. Lee MJ, Mhawech-Fauceglia P, Lee N, Parsanian LC, Lin YG, Gayther SA, et al. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest 2013;93:528-42.
46. L'Espérance S, Bachvarova M, Tetu B, Mes-Masson AM, Bachvarov D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 2008;9:99.
47. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, et al. A non-RGDbased integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006;5:2271-80.
48. Barkan D, Chambers AF. b1-Integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res 2011;17:7219-23.
49. Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 2006;94:1621-6.
50. De Belder AN, Granath K. Preparation and properties of fluorescein-labelled dextrans. Carbohydr Res 1973;30:375-8.
51. Deschout H, Hagman J, Fransson S, Jonasson J, Rudemo M, Lorén N, et al. FRAP for quantitative diffusion measurements with a laser scanning microscope. Opt Express 2010;18:22886-905.
52. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012;9:676-82.
53. Loessner D, Flegg JA, Byrne HM, Clements JA, Hutmacher DW. Growth of confined cancer spheroids: a combined experimental and mathematical modelling approach. Integr Biol 2013;5:597-605.
54. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
55. Yamada KM, Cukierman E. Modelling tissue morphogenesis and cancer in 3D. Cell 2007;130:601-10.
56. Braeckmans K, Peeters L, Sanders NN, De Smedt SC, Demeester J. Threedimensional fluorescence recovery after photobleaching with the confocal scanning laser microscope. Biophys J 2003;85:2240-52.
57. Cushing MC, Anseth KS. Materials science. hydrogel cell cultures. Science 2007;316:1133-4.
58. Buxboim A, Ivanovska IL, Discher DE. Matrix elasticity, cytoskeletal forces and physics of the nucleus: how deeply do cells "feel" outside and in? J Cell Sci 2010;123:297-308.
59. Lee J, Cuddihy MJ, Kotov NA. Three-dimensional cell culture matrices: state of the art. Tissue Eng Part B Rev 2008;14:61-86.
60. Masaro L, Zhu X. Physical models of diffusion for polymer solutions, gels and solids. Prog Polym Sci 1999;24:731-75.
61. Amsden B. Solute diffusion in hydrogels. An examination of the retardation effect. Polym Gels Networks 1998;6:13-43.
62. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz- Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010;148:3-15.
63. Karam A, Dorigo O. MMPs in ovarian cancer as therapeutic targets. Anticancer Agents Med Chem 2012;12:764-72.
64. Kenny HA, Lengyel E. MMP-2 functions as an early response protein in ovarian metastasis. Cell Cycle 2009;8:683-8.
65. Dahl KDC, Symowicz J, Ning Y, Gutierrez E, Fishman DA, Adley BP, et al. Matrix metalloproteinase-9 is a mediator of epidermal growth factor-dependent Ecadherin loss in ovarian carcinoma cells. Cancer Res 2008;68:4606-13.
66. Do TV, Kubba LA, Du H, Sturgis CD, Woodruff TK. Transforming growth factorb1, and -b3 enhance ovarian cancer metastatic potential by inducing a Smad3- dependent epithelial-to-mesenchymal transition. Mol Cancer Res 2008;6:695-705.
67. Schmalfeldt B, Prechtel D, Härting K, Rutke S, Konik E, Fridman R, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9 and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001;7:2396-404.
68. Toole BP. Hyaluronan promotes the malignant phenotype. Glycobiology 2002;12:37R-42.
69. Byers LJ, Osborne JL, Carson LF, Carter JR, Haney AF, Weinberg JB, et al. Increased levels of laminin in ascitic fluid of patients with ovarian cancer. Cancer Lett 1995;88:67-72.
70. Kutty JK, Cho E, Lee JS, Vyavahare NR, Webb K. The effect of hyaluronic acid incorporation on fibroblast spreading and proliferation within PEG-diacrylate based semi-interpenetrating networks. Biomaterials 2007;28:4928-38.
71. Levett P, Melchels FPW, Schrobback K, Hutmacher DW, Malda J, Klein T. A biomimetic extracellular matrix for cartilage tissue engineering centered on photocurable gelatin, hyaluronic acid and chondroitin sulfate. Acta Biomater 2014;10:214-23.